Zhejiang Normal University discloses new RET inhibitors
Zhejiang Normal University has patented new inhibitors of proto-oncogene tyrosine-protein kinase receptor Ret (RET; CDHF12; PTC) and its mutants potentially use...
Zhejiang Normal University has patented new inhibitors of proto-oncogene tyrosine-protein kinase receptor Ret (RET; CDHF12; PTC) and its mutants potentially useful for the treatment of cancer.